Open AccessThe combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)
Author(s) -
Faith E. Davies,
Ping Wu,
Matthew Jenner,
Muralikrishan Srikanth,
Radovan Sašo,
Gareth J. Morgan
Publication year - 2007
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.11228
Subject(s) - dexamethasone , bortezomib , medicine , toxicity , cyclophosphamide , neutropenia , multiple myeloma , pharmacology , refractory (planetary science) , oncology , chemotherapy , physics , astrobiology
The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.